3Krieger JN, Riley DE, Vesella RL, et al. Bacterial DNA sequences in prostate tissue from patients with prostate cancer and chronic prostatitis [ J ]. J Urol, 2000, 164 (4) : 1221 - 1228.
2Tanner MA, Shoskes D, Shahed A, et al. Prevalence of coryndbacterial 16 S rRNA sequences in patients with bacterial and nonbacterial" prostatitis [ J ]. Clin Microbiol, 1999,37 ( 6 ): 1863-1870.
4Barbanoj MJ, Antonijoan RM, Gich I. Clinical pharmacoknietics of dexketoprofen. Clin Pharmacokinet, 2001, 40(4) : 245-262.
5Shoskes DA, Thomas KD, Gomez E. Anti-nanobacterial therapy for men with chronic prostatitis/chronic pelvic pain syndrome and prostatic stones: preliminary experience. J Urol, 2005, 173(2) : 474-477.
6Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol, 2004, 172(3) : 839-845.
7Datta NS. Role of or-blockers in the treatment of chronic prostatitis. Urology, 2002, 60(6 Suppl) : 27-28.
8Cheab PY, Liong ML, Yuen KH, et al. Initial,long-term,and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology, 2004, 64(5) : 881-886.
9Evans AM. Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S( + )-ibuprofen. J Clin Pharmacol, 1996, 36(12 Suppl) : 7S-15S.
10Krieger JN, Riley DE, Cheah PY, et al. Epidemiology of prostatitis: new evidence for a world-wide problem [J]. World J Urol,2.003, 21 (2) :70-74.
